Clinical trials: Immunosuppression
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
Kidney Transplantation
Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.
Primary objective of this study is to compare the renal function as well as the incidence of renal dysfunction, the incidence of death, graft loss and acute rejection.
- Trial name
- SENIOR (NCT00296309)
- Testing
- Tacrolimus
- Where
- 33 sites in Belgium, France and 5 more
- Volunteers
- 267 people
- Sponsor
- Astellas Pharma Inc
Liver Transplantation
A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients
A proof of concept study to evaluate the safety and effectiveness of FK778 in liver transplant patients.
- Trial name
- NCT00451932
- Testing
- FK778
- Where
- 29 sites in Austria, Belgium and 10 more
- Volunteers
- 303 people
- Sponsor
- Astellas Pharma Inc
Autoimmune Liver Disease, Autoimmune Hepatitis
TruGraf Liver Gene Expression Serial Test
This is an Investigator Initiated, single center, non-randomized, single arm study utilizing TruGraf liver gene expression serial testing in patients with autoimmune liver diseases (AIH, PSC, PBC) monthly for the first 6 months…
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
- Trial name
- NCT06061341
- Testing
- TruGraf®
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndromes
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
This study will evaluate the safety and effectiveness of a genetically engineered antibody, alemtuzumab (Campath[R]) on patients with myelodysplastic syndrome.
- Trial name
- NCT00217594
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myocarditis, Heart Failure
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
Myocarditis can result in numerous complications, but there is paucity of data regarding optimal therapy, short- and long-term effects of possibly effective immunosuppressive therapy.
- Conditions
- Myocarditis, Heart Failure, Endomyocardial Biopsy, Cardiomyopathies, Secondary
- Trial name
- IMPROVE-MC (NCT04654988)
- Testing
- Prednisone, Azathioprine
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Sepsis, ARDS
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation.
- Conditions
- Sepsis, ARDS, Critical Illness, Neurocognitive Dysfunction
- Trial name
- ESTABLISH (NCT05591924)
- Testing
- Phelebotomy, Broncheoalveolar Lavage, Tracheal Aspirate
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Renal Transplant Rejection
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
As the patents for brand-name immunosuppressive medications expire, there is increasing interest in using generic immunosuppressive drugs.
- Trial name
- NCT02866682
- Testing
- Prograf, Tacrolimus
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- University of California, Los Angeles
Liver Transplant Rejection, Immune System Suppression
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.
- Trial name
- NCT05655273
- Testing
- Prograf, Envarsus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Renal Cell, Carcinoma Colon
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Bexmarilimab treatment has demonstrated tolerable safety profile and anticancer efficacy in some subjects with advanced malignancies.
- Trial name
- RENACOL (NCT05104905)
- Testing
- bexmarilimab
- Where
- Finland
- Sponsor
- Faron Pharmaceuticals Ltd
Function of Renal Transplant
RituxiMab INDuction in Renal Transplantation
Hypothesis: That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival.
- Trial name
- ReMIND (NCT01095172)
- Testing
- Rituximab, Tacrolimus, Mycophenylate mofetil
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Autoimmune Disease
Rituximab for Autoimmune Retinopathy
Background: Autoimmune retinopathy (AIR) is an inflammatory condition in which the patient s own immune system is attacking his or her eyes and causing vision loss.
- Trial name
- NCT01086631
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Renal Transplantation
3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation
Renal transplantation represents currently the best therapeutic alternative for end-stage renal failure, not only in terms of patient outcomes (better quality of life and longer survival), but also in terms of costs for the…
- Trial name
- I4BiS (NCT02444429)
- Testing
- Corticosteroid boluses Methylprednisolone, No therapeutic modification, Stop maintenance corticotherapy
- Where
- 8 sites in France
- Volunteers
- 346 people
- Sponsor
- Hospices Civils de Lyon
Kidney Transplantation
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
The purpose of this study is to compare the safety and efficacy of a tacrolimus-based 5-day steroid rapid withdrawal immunoprophylactic regimen in de novo renal transplantation.
- Trial name
- NCT00133172
- Testing
- Tacrolimus, mycophenolate mofetil, Prednisone
- Where
- 14 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Astellas Pharma Inc
Sepsis
Project 4A: Inspiratory Muscle Training and Diaphragm Strength
Investigators will assess the effect of exercise on markers of inflammation and protein catabolism. This research study will further our understanding of how treating Chronic Critical illness (CCI) - related respiratory muscle…
- Trial name
- NCT02367170
- Testing
- Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Multiple Sclerosis, B-Cell Deficiency
B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment
The overall aim of the study is to gain knowledge about consequences for the child´s humoral immunosystem in mothers with multiple sclerosis and due to their immunomodulating treatments.
- Conditions
- Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult, Immunosuppression
- Trial name
- NCT06711354
- Testing
- Anti-CD20 Monoclonal Antibody
- Volunteers
- 111 people
- Sponsor
- Region Stockholm
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Rejection Heart Transplant, Immunosuppression
Improving Immunosuppressive Therapy in Heart Transplantation
Cardiac allograft rejection (CAR) occurs in 30% to 40% of transplant recipients within the first year post-transplant, and carries an increased risk of both acute graft failure and reduced graft longevity.
- Trial name
- NCT03932539
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Juvenile Rheumatoid Arthritis, Uveitis
TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
This study will investigate the safety and effectiveness of the drug TNFR:Fc to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.
- Trial name
- NCT00001862
- Testing
- Enbrel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Duchenne Muscular Dystrophy
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients
This Phase I/II of the clinical trial is to investigate whether the transplantation of normal myoblasts throughout one muscle (the extensor carpi radialis) of the patients is safe and will improve the strength of that muscle.
- Trial name
- NCT02196467
- Testing
- Myoblast transplantation, Saline injection
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- CHU de Quebec-Universite Laval